Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Thoracic 6Tumor-Agnostic 3Gastrointestinal 3CNS 3Dermatologic 2Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Endocrine 1

Conditions

Neoplasm Metastasis 2Neoplasms 1

Interventions

Surveys and Questionnaires 70Blood Specimen Collection 48Radiotherapy 39Magnetic Resonance Spectroscopy 35pembrolizumab 31Gemcitabine 30Bevacizumab 30Nivolumab 29Carboplatin 29Radiosurgery 27Standard of Care 26Oxaliplatin 26Capecitabine 25Paclitaxel 24Interviews as Topic 24Cisplatin 24Fluorouracil 23Erlotinib Hydrochloride 22Everolimus 19Irinotecan 18Trastuzumab 17Methods 17Exercise 17Docetaxel 17Biopsy 17Cyclophosphamide 16Educational Status 15Sorafenib 14Ipilimumab 14Fluorodeoxyglucose F18 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × ceritinib × Tumor-Agnostic × Clear all
NCT02321501 2026-05-20

Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
37 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT04817956 2024-02-29

IMPRESS-N

Oslo University Hospital

Phase 2 Recruiting
3,000 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT05467189 2022-07-20

Antineoplastic Drugs in Elderly Patients

Shandong University

Recruiting
500 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡